| Literature DB >> 27211075 |
Bas van der Woning1, Gitte De Boeck1, Christophe Blanchetot1, Vladimir Bobkov1,2, Alex Klarenbeek3, Michael Saunders1, Magali Waelbroeck4, Toon Laeremans5, Jan Steyaert5,6, Anna Hultberg1, Hans De Haard1.
Abstract
The identification of functional monoclonal antibodies directed against G-protein coupled receptors (GPCRs) is challenging because of the membrane-embedded topology of these molecules. Here, we report the successful combination of llama DNA immunization with scFv-phage display and selections using virus-like particles (VLP) and the recombinant extracellular domain of the GPCR glucagon receptor (GCGR), resulting in glucagon receptor-specific antagonistic antibodies. By immunizing outbred llamas with plasmid DNA containing the human GCGR gene, we sought to provoke their immune system, which generated a high IgG1 response. Phage selections on VLPs allowed the identification of mAbs against the extracellular loop regions (ECL) of GCGR, in addition to multiple VH families interacting with the extracellular domain (ECD) of GCGR. Identifying mAbs binding to the ECL regions of GCGR is challenging because the large ECD covers the small ECLs in the energetically most favorable 'closed conformation' of GCGR. Comparison of Fab with scFv-phage display demonstrated that the multivalent nature of scFv display is essential for the identification of GCGR specific clones by selections on VLPs because of avid interaction. Ten different VH families that bound 5 different epitopes on the ECD of GCGR were derived from only 2 DNA-immunized llamas. Seven VH families demonstrated interference with glucagon-mediated cAMP increase. This combination of technologies proved applicable in identifying multiple functional binders in the class B GPCR context, suggesting it is a robust approach for tackling difficult membrane proteins.Entities:
Keywords: DNA immunizations; glucagon receptor; llama; phage display; single-chain Fv; virus-like particles
Mesh:
Substances:
Year: 2016 PMID: 27211075 PMCID: PMC4968103 DOI: 10.1080/19420862.2016.1189050
Source DB: PubMed Journal: MAbs ISSN: 1942-0862 Impact factor: 5.857